ATHENA HAS SUCCESSFULLY
Developed Products which has been
Launched by our clients
Athena has been dedicated to develop lifecycle products and has developed a broad range of technology platforms for oral delivery with a special focus on modified release formulation as well as oro-dispersible dosage forms. Using this technologies Athena has developed wide range of products in various therapeutic segments like Pain, CNS, Cardiovascular, Diabetes , gastroenterology ect.
A BOARD RANGE
DRUG DELIVERY PLATFORM
In Type II Diabetes management Athena has successfully launched products like Voglibose 0.2 mg / 0.3mg Orally Disintegrating Tablet and Metformin 500mg + Voglibose 0.2mg/0.3mg Tablet with valued partners like AstraZeneca and Novartis in Emerging markets.
In Gastro segment, Athena has innovated by developing and launching products like Mesalamine 500mg / 1000mg Sachet marketed under the trade name Rowasa® marketed by Abbott and Domperidone 10mg Orally disintegrating Tablet marketed under the trade name Emiges® marketed by Ranbaxy in Malaysia.
Drugs acting on CNS, is an area where oral drug delivery has given proven results in reviving some old molecules after introducing newer lifecycle products such as Prochlorperazine 5mg Orally Disintegrating Tablet, Zolpidem 5mg Orally Disintegrating Tablet, Levocetirizine Orally disintegrating Tablet.
Pain Management has always been a rewarding segment for Athena with some successful launches like Tramadol 50mg Orally disintegrating Tablet marketed under the trade name Trambax® marketed by Ranbaxy and some ongoing registrations like Meloxicam Orally disintegrating Tablet.
Secnidazole 2000mg Sachet is a one-shot treatment of Bacterial Vaginosis which is equivalent to 7 days Bid dose of Metronidazole Tablet. This brings a unique compliance advantage.